A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8527 Monotherapy in Anti-Retroviral Therapy (ART)-Naive, HIV-1 Infected Participants
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs MK-8527 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 02 Dec 2019 Planned End Date changed from 13 Jan 2020 to 13 Feb 2020.
- 02 Dec 2019 Planned primary completion date changed from 13 Jan 2020 to 13 Feb 2020.
- 25 Oct 2019 Planned End Date changed from 13 Dec 2019 to 13 Jan 2020.